TR201908031T4 - İdrar kesesi hastalıklarının tedavisine yönelik muskarinik m3 ligandları olarak 2-aminotiyazol türevleri veya bunların tuzu. - Google Patents
İdrar kesesi hastalıklarının tedavisine yönelik muskarinik m3 ligandları olarak 2-aminotiyazol türevleri veya bunların tuzu. Download PDFInfo
- Publication number
- TR201908031T4 TR201908031T4 TR2019/08031T TR201908031T TR201908031T4 TR 201908031 T4 TR201908031 T4 TR 201908031T4 TR 2019/08031 T TR2019/08031 T TR 2019/08031T TR 201908031 T TR201908031 T TR 201908031T TR 201908031 T4 TR201908031 T4 TR 201908031T4
- Authority
- TR
- Turkey
- Prior art keywords
- bladder
- muscarinic
- salt
- urinary tract
- tract diseases
- Prior art date
Links
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical class NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 title abstract 3
- 208000026533 urinary bladder disease Diseases 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 2
- 239000003446 ligand Substances 0.000 title 1
- 230000003551 muscarinic effect Effects 0.000 title 1
- 102000007202 Muscarinic M3 Receptor Human genes 0.000 abstract 3
- 108010008405 Muscarinic M3 Receptor Proteins 0.000 abstract 3
- 208000012931 Urologic disease Diseases 0.000 abstract 3
- 208000014001 urinary system disease Diseases 0.000 abstract 3
- 230000008602 contraction Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 206010013990 dysuria Diseases 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 208000029162 bladder disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 239000003223 protective agent Substances 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
İdrar kesesi bozuklukları, disüri, alt idrar yolu hastalıkları ve benzerlerinin tedavi edilmesi için bir farmasötik bileşimde bir aktif bileşen olarak faydalı bir bileşiğin sağlanmasına yöneliktir. [Çözüm] Mevcut buluşun buluş sahipleri, bir 2-aminotiyazol türevinin mükemmel bir muskarinik M3 reseptörü pozitif allosterik modülatör aktivitesi gösterdiğini ve muskarinik M3 reseptörleri aracılı idrar kesesi kasılmasının katkıda bulunduğu idrar kesesi ve idrar yolu hastalıklarına karşı bir koruyucu veya terapötik ajan olarak potansiyele sahip olduğunu bulmuştur. 2-aminotiyazol türevi veya bunun tuzu, örneğin yetersiz idrar kesesini kapsayan disüri gibi idrar kesesi veya idrar yolu hastalıklarına karşı ve muskarinik M3 reseptörleri aracılı idrar kesesi kasılmasının katkıda bulunduğu bir koruyucu veya terapötik ajan olarak potansiyele sahiptir.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014171092 | 2014-08-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201908031T4 true TR201908031T4 (tr) | 2019-06-21 |
Family
ID=55399719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/08031T TR201908031T4 (tr) | 2014-08-26 | 2015-08-25 | İdrar kesesi hastalıklarının tedavisine yönelik muskarinik m3 ligandları olarak 2-aminotiyazol türevleri veya bunların tuzu. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9844549B2 (tr) |
| EP (1) | EP3196200B1 (tr) |
| JP (1) | JP6569678B2 (tr) |
| KR (1) | KR20170042608A (tr) |
| CN (1) | CN106573928B (tr) |
| BR (1) | BR112017003901A2 (tr) |
| CA (1) | CA2959290A1 (tr) |
| ES (1) | ES2736098T3 (tr) |
| MX (1) | MX2017002500A (tr) |
| PL (1) | PL3196200T3 (tr) |
| PT (1) | PT3196200T (tr) |
| RU (1) | RU2702106C2 (tr) |
| TR (1) | TR201908031T4 (tr) |
| WO (1) | WO2016031833A1 (tr) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1169038E (pt) | 1999-04-15 | 2012-10-26 | Bristol Myers Squibb Co | Inibidores cíclicos da proteína tirosina cinase |
| ES2416304T3 (es) * | 2002-01-18 | 2013-07-31 | Astellas Pharma Inc. | Derivado de 2-acilaminotiazol o sal del mismo |
| WO2003087064A1 (en) * | 2002-04-18 | 2003-10-23 | Ucb, S.A. | Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions |
| EP1647553A4 (en) | 2003-07-17 | 2008-12-31 | Astellas Pharma Inc | 2-ACYLAMINOTHIAZOL DERIVATIVE OR SALT THEREOF |
| GB0516313D0 (en) * | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
| US20100056565A1 (en) * | 2007-02-15 | 2010-03-04 | Argenta Discovery Limited | Heterocyclic Derivatives as M3 Muscarinic Receptors |
| EP2206707B1 (en) * | 2007-10-24 | 2014-07-23 | Astellas Pharma Inc. | Azolecarboxamide compound or salt thereof |
| KR101764952B1 (ko) * | 2010-07-29 | 2017-08-03 | 리겔 파마슈티칼스, 인크. | Ａｍｐｋ-활성화 헤테로시클릭 화합물 및 그의 사용 방법 |
| TW201208667A (en) * | 2010-08-03 | 2012-03-01 | Altherx Inc | Pharmaceutical combinations |
| CA2860008C (en) * | 2011-12-22 | 2020-11-10 | Dominique Swinnen | Tetraaza-cyclopenta[a]indenyl and their use as positive allosteric modulators |
| JP6211509B2 (ja) * | 2012-03-02 | 2017-10-11 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| WO2014077401A1 (ja) | 2012-11-19 | 2014-05-22 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| TWI647227B (zh) | 2013-02-28 | 2019-01-11 | 日商安斯泰來製藥股份有限公司 | ２－醯胺噻唑衍生物或其鹽 |
| MA39950B1 (fr) | 2014-06-06 | 2019-08-30 | Astellas Pharma Inc | Dérivé de 2-acylaminothiazole pour le traitement des maladies des voies urinaires et de la vessie |
-
2015
- 2015-08-25 CA CA2959290A patent/CA2959290A1/en not_active Abandoned
- 2015-08-25 MX MX2017002500A patent/MX2017002500A/es unknown
- 2015-08-25 PL PL15836701T patent/PL3196200T3/pl unknown
- 2015-08-25 CN CN201580045374.8A patent/CN106573928B/zh not_active Expired - Fee Related
- 2015-08-25 KR KR1020177004905A patent/KR20170042608A/ko not_active Application Discontinuation
- 2015-08-25 TR TR2019/08031T patent/TR201908031T4/tr unknown
- 2015-08-25 ES ES15836701T patent/ES2736098T3/es active Active
- 2015-08-25 WO PCT/JP2015/073914 patent/WO2016031833A1/ja active Application Filing
- 2015-08-25 US US15/506,561 patent/US9844549B2/en active Active
- 2015-08-25 RU RU2017105450A patent/RU2702106C2/ru active
- 2015-08-25 EP EP15836701.1A patent/EP3196200B1/en active Active
- 2015-08-25 JP JP2016545558A patent/JP6569678B2/ja not_active Expired - Fee Related
- 2015-08-25 BR BR112017003901A patent/BR112017003901A2/pt not_active IP Right Cessation
- 2015-08-25 PT PT15836701T patent/PT3196200T/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3196200B1 (en) | 2019-05-08 |
| CN106573928A (zh) | 2017-04-19 |
| US20170290824A1 (en) | 2017-10-12 |
| JP6569678B2 (ja) | 2019-09-04 |
| EP3196200A4 (en) | 2018-02-28 |
| BR112017003901A2 (pt) | 2017-12-12 |
| RU2702106C2 (ru) | 2019-10-04 |
| WO2016031833A1 (ja) | 2016-03-03 |
| KR20170042608A (ko) | 2017-04-19 |
| EP3196200A1 (en) | 2017-07-26 |
| MX2017002500A (es) | 2017-05-23 |
| PL3196200T3 (pl) | 2019-09-30 |
| CN106573928B (zh) | 2020-04-14 |
| CA2959290A1 (en) | 2016-03-03 |
| US9844549B2 (en) | 2017-12-19 |
| RU2017105450A (ru) | 2018-09-27 |
| RU2017105450A3 (tr) | 2019-03-19 |
| PT3196200T (pt) | 2019-06-17 |
| ES2736098T3 (es) | 2019-12-26 |
| JPWO2016031833A1 (ja) | 2017-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020004950A (es) | Compuestos arilo, heteroarilo, y heterocíclicos para el tratamiento de trastornos mediados por complemento. | |
| EA201591727A1 (ru) | Соединения биариламида в качестве ингибиторов киназы | |
| EA201790088A1 (ru) | Ингибиторы syk | |
| PH12017500401A1 (en) | Therapeutic compounds as inhibitors of the orexin-1 receptor | |
| TR201816176T4 (tr) | Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler. | |
| PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| SA515360956B1 (ar) | مشتق من 2-أسيل امينو ثيازول أو ملح من أملاحه | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
| WO2016004404A3 (en) | Gls1 inhibitors for treating disease | |
| PH12016502405A1 (en) | 2-acylaminothiazole derivative or salt thereof | |
| MY201535A (en) | Therapeutic compounds | |
| WO2016004413A3 (en) | Gls1 inhibitors for treating disease | |
| BR112016026552A8 (pt) | derivados de carboxamida, seus usos, composição farmacêutica, e combinação | |
| EA201792264A1 (ru) | Способы лечения воспалительных заболеваний | |
| EA201891439A1 (ru) | Трициклические соединения и их композиции в качестве ингибиторов киназ | |
| TR201908151T4 (tr) | İzoindolin türevleri. | |
| EA201691058A1 (ru) | Производные пирролопирролона и их применение для лечения заболеваний | |
| MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. | |
| TR201908031T4 (tr) | İdrar kesesi hastalıklarının tedavisine yönelik muskarinik m3 ligandları olarak 2-aminotiyazol türevleri veya bunların tuzu. | |
| EA201790020A1 (ru) | Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний | |
| BR112017016065A2 (pt) | prevenção ou tratamento de ácido úrico ou doença gotosa | |
| MX2019014773A (es) | Inhibidores de ccl2. | |
| EA202091668A2 (ru) | Ингибиторы калликреина плазмы человека |